Cargando…

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Her...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Vidhatha, Myers, Bridget, Yang, Eric J, Bhutani, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295208/ https://www.ncbi.nlm.nih.gov/pubmed/32606876 http://dx.doi.org/10.2147/CCID.S252426

Ejemplares similares

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022)

Erbium-doped (Pb(0.9)-Er(0.01)-Zr(0.09)) and (Pb(0.9)-Er(0.01)-Zr(0.045)-Ti(0.045)) nano-crystalline films and nano-rods ceramic synthesis by sol–gel technique for energy-storage application
por: Ibrahim, F. A., et al.
Publicado: (2023)

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential
por: Laquer, Vivian, et al.
Publicado: (2021)

Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055
por: Stahl, KW, et al.
Publicado: (2011)

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022)

0.045% DAC N-055 a choice for poor Afghan surgical patients?
por: Stahl, KW, et al.
Publicado: (2011)

A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel
por: Vollono, Laura, et al.
Publicado: (2020)

Performance Optimization of Pb(0.97)La(0.03)Sc(0.45)Ta(0.45)Ti(0.1)O(3) Ceramics by Annealing Process
por: Su, Zihan, et al.
Publicado: (2023)

Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis
por: Sobhan, Mohammadreza, et al.
Publicado: (2019)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

EVALUATION OF TOPICAL 0.1% TAZAROTENE CREAM IN THE TREATMENT OF PALMOPLANTAR PSORIASIS: AN OBSERVER-BLINDED RANDOMIZED CONTROLLED STUDY
por: Mehta, Bijal H, et al.
Publicado: (2011)

Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin
por: Carvajal-Vidal, Paulina, et al.
Publicado: (2017)

Effect of atropine 0.01% on progression of myopia
por: Sen, Snigdha, et al.
Publicado: (2022)

Compounded 0.01% Atropine—What's in the Bottle?
por: Richdale, Kathryn, et al.
Publicado: (2023)

Effectiveness of 0.01% atropine in anisomyopic children
por: Hussain, Azfira, et al.
Publicado: (2023)

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery
por: Jung, Ji Won, et al.
Publicado: (2015)

Effect of 0.01% Atropine on Accommodation in Myopic Teenagers
por: Li, Huixia, et al.
Publicado: (2022)

Ocular pharmacokinetics of 0.45% ketorolac tromethamine
por: Attar, Mayssa, et al.
Publicado: (2010)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Development of Perovskite (MACl)(0.33)FA(0.99)MA(0.01)Pb(I(0.99)Br(0.01))(3) Solar Cells via n-Octylammonium Iodide Surface Passivation
por: Osman, M. M., et al.
Publicado: (2023)

In vitro and in vivo degradation behavior of Mg-0.45Zn-0.45Ca (ZX00) screws for orthopedic applications
por: Martinez, Diana C., et al.
Publicado: (2023)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

The Effects of 0.01% Atropine on Adult Myopes’ Contrast Sensitivity
por: Cheng, Ziyun, et al.
Publicado: (2021)

Effects of atropine 0.01% on refractive errors in children with myopia
por: Zhu, Xingxue, et al.
Publicado: (2023)

Anomalous behavior above the Curie temperature in (Nd(1−x)Gd(x))(0.55)Sr(0.45)MnO(3) (x = 0, 0.1, 0.3 and 0.5)
por: Kamel, R., et al.
Publicado: (2019)

Tunable and Passively Mode-Locking Nd(0.01):Gd(0.89)La(0.1)NbO(4) Picosecond Laser
por: Liu, Shande, et al.
Publicado: (2021)

Effect of 0.02% and 0.01% atropine on astigmatism: a two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2022)

Theoretical Luminosity Precision for the FCC-ee: Overview of the Path to 0.01%
por: Ward, Bennie F L, et al.
Publicado: (2019)

Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children
por: Zhao, Qi, et al.
Publicado: (2020)

Comparison of Skin Antiseptic Agents and the Role of 0.01% Hypochlorous Acid
por: Tran, Ann Q, et al.
Publicado: (2020)

Calibration-free NGS quantitation of mutations below 0.01% VAF
por: Dai, Peng, et al.
Publicado: (2021)

Characteristics of responders to atropine 0.01% as treatment in Asian myopic children
por: Lee, Lung-Chi, et al.
Publicado: (2022)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan
por: Stahl, Hans-Christian, et al.
Publicado: (2014)

Comparison of topical clobetasol propionate 0.05% and topical tacrolimus 0.1% in the treatment of cutaneous lichen planus
por: Özkur, Ezgi, et al.
Publicado: (2020)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Enhanced Thermoelectric Properties of Te Doped Polycrystalline Sn(0.94)Pb(0.01)Se
por: Li, Fujin, et al.
Publicado: (2022)

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tbsgevlmm6e5i0tckdgur1tvf5